Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 524

Similar articles for PubMed (Select 23134716)

2.

Measurement properties of the benign prostatic hyperplasia impact index in tadalafil studies.

Angalakuditi M, Seifert RF, Hayes RP, O'Leary MP, Viktrup L.

Health Qual Life Outcomes. 2010 Nov 12;8:131. doi: 10.1186/1477-7525-8-131.

3.

Patient-reported outcomes in men with lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) treated with intraprostatic OnabotulinumtoxinA: 3-month results of a prospective single-armed cohort study.

Sacco E, Bientinesi R, Marangi F, Totaro A, D'Addessi A, Racioppi M, Pinto F, Vittori M, Bassi P.

BJU Int. 2012 Dec;110(11 Pt C):E837-44. doi: 10.1111/j.1464-410X.2012.11288.x. Epub 2012 Jun 19.

PMID:
22712582
6.

Tadalafil once daily in the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH) in men without erectile dysfunction.

Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L.

BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13.

PMID:
23937669
7.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

Porst H, Kim ED, Casabé AR, Mirone V, Secrest RJ, Xu L, Sundin DP, Viktrup L; LVHJ study team.

Eur Urol. 2011 Nov;60(5):1105-13. doi: 10.1016/j.eururo.2011.08.005. Epub 2011 Aug 12.

PMID:
21871706
8.

Assessment of lower urinary tract symptoms in men by international prostate symptom score and core lower urinary tract symptom score.

Fujimura T, Kume H, Nishimatsu H, Sugihara T, Nomiya A, Tsurumaki Y, Miyazaki H, Suzuki M, Fukuhara H, Enomoto Y, Homma Y.

BJU Int. 2012 May;109(10):1512-6. doi: 10.1111/j.1464-410X.2011.10445.x. Epub 2011 Aug 26.

PMID:
21883834
9.

A randomised, placebo-controlled study to assess the efficacy of twice-daily vardenafil in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia.

Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E.

Eur Urol. 2008 Jun;53(6):1236-44. doi: 10.1016/j.eururo.2008.01.075. Epub 2008 Feb 4.

PMID:
18281145
11.

Naftopidil for the treatment of lower urinary tract symptoms compatible with benign prostatic hyperplasia.

Garimella PS, Fink HA, Macdonald R, Wilt TJ.

Cochrane Database Syst Rev. 2009 Oct 7;(4):CD007360. doi: 10.1002/14651858.CD007360.pub2. Review.

PMID:
19821408
12.

Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial.

Oelke M, Giuliano F, Mirone V, Xu L, Cox D, Viktrup L.

Eur Urol. 2012 May;61(5):917-25. doi: 10.1016/j.eururo.2012.01.013. Epub 2012 Jan 20.

PMID:
22297243
15.

Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study.

Egerdie RB, Auerbach S, Roehrborn CG, Costa P, Garza MS, Esler AL, Wong DG, Secrest RJ.

J Sex Med. 2012 Jan;9(1):271-81. doi: 10.1111/j.1743-6109.2011.02504.x. Epub 2011 Oct 7.

PMID:
21981682
16.

Outcomes and general health-related quality of life among patients medically treated in general daily practice for lower urinary tract symptoms due to benign prostatic hyperplasia.

Fourcade RO, Lacoin F, Rouprêt M, Slama A, Le Fur C, Michel E, Sitbon A, Cotté FE.

World J Urol. 2012 Jun;30(3):419-26. doi: 10.1007/s00345-011-0756-2. Epub 2011 Sep 3.

17.

Effect of tamsulosin hydrochloride on lower urinary tract symptoms and quality of life in patients with benign prostatic hyperplasia. Evaluation using bother score.

Yoshida M, Sugiyama Y, Masunaga K, Maeda Y, Satoji Y, Nagata T, Inadome A.

Drugs Today (Barc). 2007 Jun;43 Suppl B:1-7.

PMID:
17612712
18.

Improvements in benign prostatic hyperplasia-specific quality of life with dutasteride, the novel dual 5alpha-reductase inhibitor.

O'Leary MP, Roehrborn C, Andriole G, Nickel C, Boyle P, Höfner K.

BJU Int. 2003 Aug;92(3):262-6.

PMID:
12887480
19.

Evaluation of Tadalafil effect on lower urinary tract symptoms of benign prostatic hyperplasia in patients treated with standard medication.

Madani AH, Afsharimoghaddam A, Roushani A, Farzan A, Asadollahzade A, Shakiba M.

Int Braz J Urol. 2012 Jan-Feb;38(1):33-9.

20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk